Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association
May 18 2017 - 6:12AM
Business Wire
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of
next-generation therapeutics for the treatment of
complement-mediated diseases, today announced that data on the
Company’s first-in-class, oral small molecule complement C5 program
will be presented at the 22nd Congress of the European Hematology
Association (EHA) from June 22-25, 2017 in Madrid, Spain.
Inhibition of C5 is a clinically validated approach for the control
of complement-induced hemolysis in patients with paroxysmal
nocturnal hemoglobinuria (PNH).
Details of the oral presentation are as follows:
Title: Discovery of Orally Bioavailable Small Molecules
for Inhibition of Complement C5Session Title: Bone marrow
failure and PNH (oral presentation)Presenter: Alonso
Ricardo, Ph.D., Senior Vice President and Head of Research, Ra
PharmaDate/Time: Saturday, June 24, 5:00- 5:15 PM
CESTLocation: Room N104Abstract Code: S500
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
complement-mediated diseases. The Company discovers and develops
peptides and small molecules to target key components of the
complement cascade. For more information, please visit:
www.rapharma.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
safety, efficacy and regulatory and clinical progress of our
product candidates, including RA101495. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include the risks that Ra Pharma’s
product candidates, including RA101495, will not successfully be
developed or commercialized; as well as the other factors discussed
in the “Risk Factors” section in Ra Pharma’s most recently filed
Annual Report on Form 10-K, as well as other risks detailed in Ra
Pharma’s subsequent filings with the Securities and Exchange
Commission. There can be no assurance that the actual results or
developments anticipated by Ra Pharma will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Ra Pharma. All information in this
press release is as of the date of the release, and Ra Pharma
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170518005408/en/
Investors:Ra Pharmaceuticals, Inc.Jennifer Robinson,
617-674-9873jrobinson@rapharma.comorMedia:Argot PartnersEliza
Schleifstein, 917-763-8106eliza@argotpartners.com
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2023 to Apr 2024